Alexion | Expanded Access Navigator

Email

managedaccess@alexion.com

ClinicalTrials.gov URL

https://clinicaltrials.gov/ct2/results?cond=&term=&spons=alexion&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d

Acknowledgement

3 business days

EA Page

https://alexion.com/alexion-managed-access-programs

COVID-19 Information

Alexion Provides Update on Phase 3 Study of ULTOMIRIS^® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19

Independent data monitoring committee recommends pausing study enrollment due to lack of efficacy in pre-specified interim analysis
Company will conduct further analysis of trial data to determine next steps
No new safety findings were observed for ULTOMIRIS use in COVID-19 –

For more information, contact us at covid.requests@alexion.com.

Stage

Expanded Access

Phase 2

Phase 3

Company Type

Late Onset Intervention